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gest that arginine-25 of apo E plays an important functionalA novel apolipoprotein E mutation, E2 (Arg25Cys), in lipopro-
role by influencing the receptor-binding ability of apo E.tein glomerulopathy.
Background. Lipoprotein glomerulopathy (LPG) is charac-
terized by intraglomerular lipoprotein thrombosis and high
plasma concentrations of apolipoprotein (apo) E. An apo E
Human apolipoprotein (apo) E, a 299 amino acid resi-variant, apo E2 (Arg145Pro) Sendai, was recently identified in
due protein, is a component of plasma triglyceride-richthree patients with LPG. We detected a novel point mutation
in the apo E gene in a patient with LPG, and we characterized and high-density lipoproteins [1]. Its primary function
the mutant apo E. appears to be the mediation of tissue uptake of triglycer-
Methods. The propositus was a 32-year-old male patient on ide-rich lipoproteins through both the low-density lipo-
maintenance hemodialysis because of LPG. The mutation was
protein (LDL) receptor and LDL receptor-related pro-detected by sequencing of genomic DNA from the patient and
tein pathways. Genetic variations at the apo E gene locuswas confirmed by restriction fragment length polymorphism
(RFLP) with Aor51HI. Recombinant apo E2 (Arg25Cys) (e2, e3, e4) code for three different major isoforms desig-
Kyoto and normal apo E3 were expressed from COS-1 cells. nated E2, E3, and E4, representing their migration char-
Low-density lipoprotein (LDL) receptor-binding activities of acteristics of isoelectric focusing (IEF). The three com-the variants were determined in an in vitro competition assay.
mon isoforms differ at polymorphic sites, arginine orResults. The propositus had the apo E phenotype E2/E4,
cysteine at codons 112 and 158. Apo E3 and apo E4 areas determined by isoelectric focusing, and the genotype e3/e4,
as determined by RFLP with HhaI. Sequence analysis of ampli- thought to bind equally well to lipoprotein receptors,
fied DNA showed a C to T transition, changing the codon whereas apo E2 (Arg158Cys) is defective, displaying ap-
for residue 25 from arginine to cysteine. The proband was a proximately 1% of the binding activity of apo E3 or apoheterozygous carrier for apo E2 (Arg25Cys) Kyoto. A family
E4 [2]. Homozygosity for apo E2 (Arg158Cys) is thestudy showed that the mother was a heterozygous carrier of
major genetic prerequisite for dysbetalipoproteinemiaapo E2 Kyoto and had dysbetalipoproteinemia, but no LPG.
The pathophysiological effect of this mutation was investigated [3]. However, the presence of certain rare mutations of
in vitro by binding studies of recombinant apo E2 Kyoto to apo E results in a dominant expression of dysbetalipo-
LDL receptors on human fibroblasts. The ability of recombi- proteinemia. To date, six dominant mutations have beennant apo E2 Kyoto to displace LDL was reduced to 10%
described [2].compared with recombinant apo E3.
Lipoprotein glomerulopathy (LPG) is a newly recog-Conclusions. Apo E2 (Arg25Cys) Kyoto is a novel mutation
of apo E that is etiologically related to LPG. However, our nized renal disease [4, 5]. It is characterized by abnormal
case indicates that the development of LPG may involve other lipoprotein deposition in the glomeruli, usually with lipo-
genetic or environmental factors. Furthermore, our data sug-
protein thrombi distending and occluding the glomerular
capillary lumina, a variable degree of mesangial prolifer-
ation, dysbetalipoproteinemia, and high levels of apo EKey words: Apo E2 (Arg25Cys) Kyoto, lipoprotein glomerulopathy,
dysbetalippoproteinemia, gene mutation, arginine 25. and apo E2/3 phenotype in most cases [6, 7]. The lipid
is demonstrable using oil red-O or Sudan stain and shows
Received for publication November 13, 1998
a layered ultrastructural appearance, suggesting that itand in revised form February 19, 1999
Accepted for publication March 24, 1999 is serially deposited within the glomerulus. Specific im-
munohistochemical staining of the glomeruli shows that 1999 by the International Society of Nephrology
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the lipid contains apo E and apo B, which are normal srl, Trieste, Italy). Ten microliters of this extract were
components of very LDL (VLDL) and their remnants, used as a template for the polymerase chain reaction
intermediate-density lipoprotein (IDL) [8]. The usual (PCR). A volume of 20 pmol of each primer was mixed
presentation of LPG includes proteinuria or nephrotic in a 100 ml reaction mixture consisting of 10 mm KCl,
syndrome, together with moderate renal impairment, 10 mm (NH4)2SO4, 20 mm Tris-HCl, pH 8.8, 2 mm MgSO4,
which ultimately progresses in many cases to chronic 0.1% Triton X-100, and 20 mm dDTPs. The mixture was
renal failure. Treatment with lipid-lowering drugs is then incubated at 968C for 10 minutes and centrifuged
sometimes effective in LPG [9], but the condition recurs briefly, and 2.5 units of Taq DNA polymerase were
in transplanted kidneys [7, 10]. There may be a racial added. The regions of primer pairs 1 (59-AAAAG
predominance in oriental people, as 23 Japanese and 3 CTTTTTGTGGAGCACCTTCTGTGTG-39) and 2 (59-
Chinese, but only 2 Caucasian cases have been reported GACCCAGAGACGACCAAGATCCTTAAGGA-39)
[11, 12]. Although the unique apo E phenotype is associ- for exon 3, 3 (59-ATCAAGCTTTCGCCCGCCCCA
ated with LPG, the relationship between the abnormality TCCCAGCCCTTC-39) and 4 (59-CGTGAATTCGCA
of apo E and LPG is not currently clear. Recently, we TGGCTGCAGGCTTCGGCGTTC-39) for exon 4 were
identified an apo E variant, apo E (Arg145Pro) Sendai, PCR amplified as follows: denatured at 968C for 30 sec-
in two Japanese kindred with LPG [13]. In the current
onds, annealed at 658C for 30 seconds, and polymerized
study, we identified a novel structural defect in apo E
at 728C for one minute for 30 cycles using a thermocyclergene in a patient with LPG and examined the functional
(Model PJ 2000; Perkin-Elmer Cetus, Norwalk, CT,implications of this mutation using in vitro binding assays
USA).with human skin fibroblasts.
DNA sequence analysis
METHODS The PCR-amplified DNA was isolated by electropho-
Characterization of plasma lipoproteins resis on a 0.8% agarose gel and ligated into pT7Blue-
T-vector (Novagen, Madison, WI, USA), as reportedBlood samples were collected in tubes containing Na2
previously [15]. Twelve clones were sequenced using theethylenediaminetetraacetic acid (EDTA) after a 12-hour
T7 DNA polymerase (Sequenase; United States Bio-fast. Plasma concentrations of cholesterol and triglycer-
chemical Co., Cleveland, OH, USA) according to theide were measured using enzymatic kits obtained from
dideoxynucleotide chain termination method.Daiichi Pure Chemicals Co. (Tokyo, Japan). Apo concen-
trations were measured by single radial immunodiffusion
Restriction fragment length polymorphism analysis(Daiichi Pure Chemicals Co.), and plasma lipoproteins
were separated by sequential ultracentrifugation. The fol- Genomic DNA was amplified by PCR using oligonu-
lowing density fractions were obtained: VLDL (d , 1.006 cleotide primers F4 (59-ACAGAATTCGCCCCGGCC
g/ml), IDL (d 5 1.006 to 1.019 g/ml), LDL (d 5 1.019 TGGTACAC-39) and F6 (59-TAAGCTTGGCACGG
to 1.063 g/ml), and high-density lipoprotein (d 5 1.063 to CTGTCCAAGGA-39) described by Emi et al [16]. For
1.21 g/ml). Control samples for comparing plasma con- the apo E genotyping, each amplification reaction was
centrations of lipids and lipoproteins were obtained from performed as described by Hixson and Vernier [17]. To
age- and gender-matched healthy subjects. IEF and im- identify the point mutation in the apo E gene, we ampli-
munoblotting were performed using polyacrylamide gels fied a 350 bp segment of the apo E gene comprising the
as described [14]. For this purpose, 10 ml of plasma were mutation in codon 25. We used the upstream primer, 59-
added to 30 ml of sialidase solution (10 mU of neuramini- CTAGGTAGCTAGATGCCTGGAC-39, and the down-
dase in 66 mm acetate buffer, pH 5.0) and incubated at
stream primer, 59-AGACTTAGCGACAGGGGCAGA
378C for two hours. Lipids were extracted from neur-
ATG-39, for PCR. Amplified DNA was digested with theaminidase-treated samples with 1.0 ml of chilled chloro-
restriction enzyme Aor51HI. The HhaI- and Aor51HI-form:methanol:ether (4:2:1, vol/vol/vol). Apo E isoforms
digested fragments were then electrophoresed on 8%were then separated by IEF on a 7.2% polyacrylamide
polyacrylamide gel at 200 V for 30 minutes, and the DNAgel containing 5 m urea and 2% ampholytes at pH 4 to
was later stained with ethidium bromide. In a search for6 and pH 5 to 8 mixed 2:1. Finally, the isoforms were
an identical mutation in the general population and thedetected by immunoblotting using goat anti-apo E anti-
patients with maintenance hemodialysis, blood specimensserum (Daiichi Pure Chemicals Co.) as the primary anti-
of 120 healthy Japanese individuals, 53 men and 67 womenbody.
aged 58 6 13, and 133 Japanese patients treated with
DNA amplification by polymerase chain reaction hemodialysis, 83 men and 50 women aged 56 6 12, were
collected and analyzed by restriction fragment length poly-Genomic DNA was isolated from 120 ml of peripheral
blood, as described in the Genomix kit manual (Talent morphism (RFLP) with Aor51HI.
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Fig. 1. Light microscopy of the renal biopsy spec-
imen. The capillary lumina are dilated by amor-
phous thrombi (PAM stain; original magnification
3770).
Mutagenesis of apo E cDNA 0.1 N NaOH. Specific LDL binding was evaluated in the
presence of a 50-fold excess of unlabeled LDL.A mutation of apo E at codon 25 consists of a substitu-
tion of CGC for TGC, which causes an amino acid change
from arginine to cysteine. We introduced this mutation RESULTS
into the normal apo E3 cDNA (a gift from Mitsubishi
Subject and analysis of plasma lipoproteins
Kagaku Co., Yokohama, Japan) using the Kunkel method
The subject was a 32-year-old Japanese male. The[18]. The mutagenic oligonucleotide carried a mismatched
clinical and histological findings of the case were pre-base for substitution of arginine to glutamine (5’ GCAG
viously reported by Komatsu et al [20]. Briefly, the pa-CCAGACCCGCGACC 39). Colonies transformed with
tient was admitted to Amagasaki Hospital on Marchthe mutated DNA were grown to produce a single-
23, 1993. The history included proteinuria in 1980 andstranded pSG5 human apo E DNA. The predicted base
bilateral pretibial edema in 1990. Renal biopsy per-sequence of the mutated apo E cDNA was confirmed
formed on September 1990 showed markedly dilatedby dideoxynucleotide sequencing as described earlier in
capillary lumina with pale-staining amorphous thrombithis article.
(Fig. 1). The concentrations of plasma lipoproteins in
members of the apo E2 Kyoto family are shown in Table 1.Expression of apo E in COS-1 cells
On admission, proband’s plasma total cholesterol, tri-
Recombinant apo E2 Kyoto and normal apo E3 were glyceride, and apo E levels were 532, 489, and 29.6
expressed from COS-1 cells as previously described [15]. mg/dl, respectively. However, renal function deterio-
The medium was collected and dialyzed against 15 mm rated progressively during the last few years, which ne-
of NH4HCO3. The recombinant apo E2 Kyoto and apo cessitated treatment with maintenance hemodialysis. He
E3 were purified by heparin-affinity chromatography, as received 10 mg pravastatin per day after starting hemodi-
described [15]. alysis, and his lipoprotein levels, including plasma LDL
cholesterol and triglyceride levels, were almost normal-
Low-density lipoprotein receptor-binding assays ized. On the other hand, plasma concentrations of HDL
Receptor-binding assays of isolated recombinant apo cholesterol were low, whereas those of triglyceride were
E-dimyristoylphosphatidylcholine (DMPC) complexes slightly elevated. The father and mother did not show
were performed using cultured human skin fibroblasts any clinical symptoms or signs of renal or cardiovascular
with a 125I-LDL competitor [15, 19]. To measure cell diseases, and they did not receive any lipid-lowering
surface binding, lipoproteins were incubated with the drugs. The concentrations of plasma VLDL cholesterol,
cell for one hour at 48C in 1 ml Dulbecco’s modified IDL cholesterol, and triglyceride of the mother were
Eagle’s medium (DMEM) containing 10 mm HEPES elevated. Although her VLDL cholesterol-to-triglycer-
without fetal bovine serum. The amount of 125I-LDL ide ratio (0.20) was lower than 0.25 [21], agarose electro-
phoresis of the plasma showed a broad b band (data notassociated with the cells was determined after lysis in
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shown). The father who had apo E3/4 phenotype showed
hypertriglyceridemia (Table 1).
Analysis of apo E phenotype and genotype
Isoelectric focusing immunoblotting for apo E and the
RFLP pattern with HhaI are shown in Figure 2 A and
B. The proband had isoform E2/4 (Fig. 2A, lane 3), with
the e3/4 genotype (Fig. 2B). The e3 codes for E3 isoform
were Cys 112 (TGC) and Arg 158 (CGC); therefore, the
E2 isoform observed in proband is considered to be the
result from a mutation other than Cys 112 and Arg 158.
DNA sequence and RFLP with Aor51HI
To explain the discrepancy between the apo E pheno-
type and genotype, we analyzed the sequence of apo E
coding region in exons 3 and 4. We identified a heterozy-
gous missense mutation (C→T) leading to an amino acid
substitution Cys (TGC) for Arg (CGC) at codon 25 (Fig.
3). Because use of the phenotype for the nomenclature
of apo E mutant has been established, the variant was
termed apo E2 (Arg25Cys) Kyoto. Apo E2 (Arg25Cys)
Kyoto mutant was confirmed by RFLP with Aor51HI
(data not shown). His mother was also heterozygous for
apo E2 (Arg25Cys) Kyoto (Table 1). Apo E2 Kyoto was
not detected by RFLP with Aor51HI in 120 healthy
Japanese subjects and 133 patients treated with mainte-
nance hemodialysis.
Low-density lipoprotein receptor-binding assays
We determined the LDL receptor-binding activities
of the variants by an in vitro competition assay. The
LDL receptor-binding activities of recombinant apo E2
(Arg25Cys) Kyoto was examined in cultured human skin
fibroblasts (Fig. 4). The LDL receptor-binding activity of
apo E2 (Arg25Cys) Kyoto was 10% of the recombinant
normal apo E3.
DISCUSSION
In this study, we identified a novel apo E mutation,
apo E2 Kyoto, in a patient with LPG. The mutant apo
E differs from apo E3 isoform by the substitution of
cysteine for arginine at position 25 of the mature protein.
The molecular basis is a point mutation in the first base
of codon 25 (C→T) of apo E gene. The renal biopsy of
this patient examined in 1990 showed enlargement of
most glomeruli and a wide dilation of the capillary lu-
mina by pale-stained amorphous thrombi [20]. The clini-
cal features of the proband were similar to those of the
nephrotic syndrome and dysbetalipoproteinemia mani-
fested by severe hypertriglyceridemia, hypercholesterol-
emia, and a broad b band on agarose gel electrophoresis
[20]. This was associated with a progressive deterioration
of renal function and development of chronic renal fail-
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ure. Among the three family members who were ana-
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Fig. 2. (A) Isoelectric focusing (IEF) and im-
munoblot analysis for apo E. Lane 1, apo E2/3;
lane 2, apo E3/4; lane 3, E2/4, a sample of
the proband. (B) Restriction fragment length
polymorphism (RFLP) analysis of the apo E
genotype. PCR-amplified DNA of the apo E
gene, including codons 112 and 158, was di-
gested with HhaI restriction. The 91 bp frag-
ment (Cys-112) and 48, 35 bp fragments from
the cleavage at the HhaI site at Arg-158
showed that the control subject had genotype
e3/3 (lane 1). The 91 bp fragment (Cys-112)
and 72, 48, and 35 bp fragments from cleavage
at the HhaI sites at Arg-112 and Arg-158
showed that the proband had genotype e3/4
(lane 2).
Fig. 3. Sequence of part of exon 3 of both
alleles of the apo E2 Kyoto propositus. The
normal apo E3 allele containing the sequence
CGC coding for amino acid 25, arginine, is
shown on the left and the mutant allele on
the right. Substitution of the apo E2 Kyoto
allele, sequence TGC, is indicated by asterisks.
lyzed, the mother was identified as a heterozygous carrier ciation with heterozygosity for apo E3 (Cys112Arg; Arg-
142Cys), apoE3 (Cys112Arg; duplication of residues 120of the mutant allele. Recombinant apo E2 Kyoto showed
only 10% of the normal receptor-binding activity in an to 126) Leiden, apo E4 (Glu13Lys; Arg145Cys) Philadel-
phia, apo E2 (Lys146Gln), and apo E1 (Lys146Glu) Har-in vitro competition assay using apo E liposomes. The
binding activity of recombinant apo E2 Kyoto to the risburg [2]. With one exception, all contain a substitution
of a nonbasic residue for arginine or lysine between 143LDL receptor was similar to other apo E mutations dom-
inantly associated with dysbetalipoproteinemia, such as and 150 of apo E [23], and display impaired LDL recep-
tor binding. Apo E2 (Arg145Pro) Sendai also containsthat of apo E1 (Lys146Glu) Harrisburg, which was 8%
of normal apo E3 [22]. a substitution of a nonbasic residue for arginine at resi-
due 145 [13]. A mutation at the same residue, apo E2Homozygosity for apo E2 (Arg158Cys) is the major
genetic prerequisite for dysbetalipoproteinemia [3]. How- (Arg145Cys), is associated with a dominant mode of
dysbetalipoproteinemia, but is not related to LPG [24].ever, the presence of certain rare mutations of apo E
results in a dominant expression of dysbetalipoproteine- It was suggested that the substitution to proline, which
is known as helix-breaker in globular proteins, may altermia. Dysbetalipoproteinemia has been reported in asso-
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only a few cases of nephropathy have been reported
[28–30]. These include a massive cluster of foam cells
containing apo B and E in the mesangial region of the
kidney. Histologically, the presence of lipoprotein
thrombi in the glomerulus, but not foam cells, is an essen-
tial feature for LPG [11]. Most reports suggest that the
pathogenesis of LPG is likely humoral in origin, rather
than specific to the kidney, although no other organ
systems have yet been shown to be affected [7, 10, 31].
However, apo E can be synthesized in the kidney as well
as in the liver and brain. In LPG, lipoproteins composed
of apo E2 Kyoto may be generated in the kidney and may
be directly involved in the abnormal lipid metabolism in
the glomerulus, particularly in the mesangium. Indeed,
Fig. 4. Binding of apo E-dimyristoylphosphatidylcholine (DMPC) com-
previous pathological studies of LPG using electron mi-plexes to low-density lipoprotein (LDL) receptors. Complexes were
prepared from DMPC and recombinant normal apo E3 (s) or apo E2 croscopy showed that various types of lipoprotein-like
(Arg25Cys) Kyoto (d). Binding to cultured human skin fibroblasts at deposits were formed in the mesangial and subendothel-
48C was determined by competition for 125I-labeled human LDL for
ial areas before lipoprotein thrombi [32–34].each preparation of complexes. Each point represents the average of
triplicate measurements. The error bars correspond to sd. In conclusion, we described a novel apo E mutation
associated with LPG. We have demonstrated that a mu-
tation of the apo E gene is etiologically related to dysbe-
talipoproteinemia and LPG. This case and the cases with
the three-dimensional conformation of apo E in a case apo E2 Sendai strongly suggest that LPG is caused by
of apo E2 Sendai [13]. However, apo E2 (Arg25Cys) mutations of apo E. However, the proband’s mother had
Kyoto is not directly related to the central portion of apo apo E Kyoto but did not develop LPG, and the presence
E in the vicinity of residues 136–158, which is involved in of carriers of apo E2 Sendai without LPG (personal
binding to the LDL receptor [2]. communication) indicates that other genetic or environ-
The primary structure of human apo E has a high mental factors seem to be necessary for the development
degree of sequence homology across species. It has been of LPG.
reported that the two most conserved regions of the
protein are the amino terminal residues 29–61 and the ACKNOWLEDGMENTS
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